NewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV EBIT

EBIT (Earnings Before Interest and Taxes) analysis for NAMS.

Quarterly EBIT

-$58.42M

↑ 15.24% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$232.04M

↑ 10.15% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin